Free Trial
OTCMKTS:IDXG

Interpace Biosciences Q1 2026 Earnings Results & Report

Interpace Biosciences logo
$6.05 0.00 (0.00%)
As of 11/13/2026 12:31 PM Eastern

Interpace Biosciences reported Q1 2026 earnings on May 12, 2026. The company reported EPS of $0.15, while revenue was $9.03 million.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
After Market Closes
Conference Call
7:00 AM ET

Interpace Biosciences EPS Results

Actual EPS
$0.15
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
1 of last 5 quarters

Interpace Biosciences Revenue Results

Actual Revenue
$9.03 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Interpace Biosciences Q1 2026 Earnings FAQ

Interpace Biosciences (OTCMKTS:IDXG) reported earnings of $0.15 per share for Q1 2026. The report was announced on Tuesday, May 12, 2026.

Interpace Biosciences reported revenue of $9.03 million for Q1 2026.

Interpace Biosciences Earnings Headlines

PDI: High Yield, Persistent Risks, But I'm Staying Invested
I'm handing you this one free
Elon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.tc pixel
See More Interpace Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Interpace Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Interpace Biosciences and other key companies, straight to your email.

About Interpace Biosciences

Interpace Biosciences (OTCMKTS:IDXG) is a molecular diagnostics company that develops and provides tests to help clinicians assess cancer risk and guide treatment decisions. Its services combine molecular analysis with pathology and related diagnostic expertise.

The company’s tests focus on conditions including pancreatic cysts and thyroid nodules. Its offerings have included PancraGEN for pancreatic cyst assessment, as well as ThyGeNEXT and ThyraMIR for evaluating thyroid nodules. Interpace has also offered molecular testing for gastrointestinal cancers.

Interpace Biosciences, formerly known as PDI, Inc., serves healthcare providers and patients primarily in the United States through its diagnostic testing services.

View Interpace Biosciences Profile